ANNX

Annexon, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1528115Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(207.0M)

EPS (Basic, as reported)

$-1.34

Net Margin FY2025

—

ROE FY2025

-97.7%

Total Equity

$212.0M

Shares Out

39M

Business description

Annexon, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (37) → (207)

Fiscal yearFY2019FY2020FY2021⚑FY2022FY2023⚑FY2024FY2025

Research & development(25)(49)(100)(113)(114)(119)(185)

General & administrative(8)(14)(31)(33)(30)(35)(32)

Total operating expenses(33)(63)(131)(146)(144)(154)(216)

Operating income(33)(63)(131)(146)(144)(154)(216)

Other income (expense), net10—————

Pre-tax income(37)(63)(130)142134138(207)

Income tax expense0——0000

Net income(37)(63)(130)(142)(134)(138)(207)

EPS — basic——($3.40)($2.60)($1.77)($1.01)($1.34)

EPS — diluted——($3.40)($2.60)($1.77)($1.01)($1.34)

Shares outstanding — basic (M)——385576137155

Shares outstanding — diluted (M)——385576137155

⚑ Weighted-average shares changed ×1.45 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.80 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.